Cinacalcet Hydrochloride

CHEMBL1200776 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
393.9 g/mol
LogP
Phase
4

The hydrochloride salt form of cinacalcet is the standard oral preparation used in patients with chronic kidney disease on dialysis to control secondary hyperparathyroidism. It should be taken with food to maximize absorption. Nausea and vomiting are common initial side effects that often improve with dose titration.

Peso Molecular

393,9000 g/mol

TPSA

12,00 Ų

Áreas Terapêuticas

Mecanismo de Ação

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl

InChI

InChI=1S/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/m1./s1

Molecular Formula

C22H23ClF3N

HBD / HBA

2 / 4

Ligações Rotacionáveis

6

Átomos Pesados

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The hydrochloride salt form of cinacalcet is the standard oral preparation used in patients with chronic kidney disease on dialysis to control secondary hyperparathyroidism. It should be taken with food to maximize absorption. Nausea and vomiting are common initial side effects that often improve with dose titration.

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Yes, Cinacalcet Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200776. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 156418. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.